Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
7.74
+0.01 (0.13%)
At close: May 20, 2026, 4:00 PM EDT
7.74
0.00 (0.00%)
After-hours: May 20, 2026, 4:04 PM EDT
Unicycive Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Unicycive Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $40.99. The average 1-year stock price forecast is 429.59% higher than the current stock price, while the lowest is $15 (+93.80%) and the highest is $90 (+1,062.79%).
Price Target: $40.99 (+429.59%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Unicycive Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $40 → $37 | Strong Buy | Maintains | $40 → $37 | +378.04% | May 13, 2026 |
| Benchmark | Benchmark | Buy Maintains $21 → $15 | Buy | Maintains | $21 → $15 | +93.80% | Apr 6, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $46 → $40 | Strong Buy | Maintains | $46 → $40 | +416.80% | Apr 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $22 | Strong Buy | Maintains | $9 → $22 | +184.24% | Oct 29, 2025 |
| Benchmark | Benchmark | Buy Maintains $3 → $21 | Buy | Maintains | $3 → $21 | +171.32% | Sep 15, 2025 |
Financial Forecast
Revenue This Year
10.89M
Revenue Next Year
420.01M
from 10.89M
Increased by 3,756.49%
EPS This Year
-1.86
from -1.67
EPS Next Year
9.38
from -1.86
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 31.5M | 1.2B | ||||||
| Avg | 10.9M | 420.0M | ||||||
| Low | 3.9M | 91.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 10,872.4% | ||||||
| Avg | - | 3,756.5% | ||||||
| Low | - | 737.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.95 | 25.26 | ||||||
| Avg | -1.86 | 9.38 | ||||||
| Low | -4.30 | 1.16 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.